Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

They do not treat the cause of Alzheimer’s disease. Kisunla offers a new approach to treat early Alzheimer’s disease. It targets the root cause of Alzheimer’s to help slow how quickly ...

Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. This drug currently isn’t known to interact with other drugs. Note: As a person’s ...

The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.

Australia's competition watchdog said on Wednesday that Singapore Telecommunications-owned Optus has reached a settlement ...

Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyloid plaque-targeting therapy with evidence to support stopping therapy when ...